CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted its application to expand the indicated age group for its Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector) (“MCV4“, trade name: Menhycia). The proposed expansion will extend coverage from “children aged 3 months to 6 years (83 months)” to “individuals aged 3 months to 17 years“, significantly broadening the vaccine’s addressable population.
Regulatory Development Timeline
Milestone
Date
Age Range Approved
Initial Marketing Approval
December 2021
Not specified in announcement
First Age Expansion
February 2026
3 months to 6 years (83 months)
Current Application Acceptance
19 Jul 2026
3 months to 17 years (pending approval)
Expected Final Approval
Q4 2026 (estimated)
Pending NMPA review completion
Product Profile & Market Significance
Product Name: Menhycia (MCV4)
Technology Platform: CRM197 carrier protein conjugate vaccine
Serogroups Covered: A, C, Y, and W135 meningococcal strains
Market Position:China’s first quadrivalent meningococcal conjugate vaccine
Current Indication: Children aged 3 months to 6 years (83 months)
Proposed Indication: Individuals aged 3 months to 17 years
Target Population Expansion: Increases addressable market by approximately 2.5x, adding adolescents aged 7-17 years
Epidemiological Rationale & Public Health Impact
Age Group
Meningococcal Disease Risk
Current Vaccination Gap
Menhycia Impact
Infants (3-12 months)
Highest incidence globally
Previously covered
Maintained protection
Young Children (1-6 years)
Elevated risk period
Currently covered
Continued coverage
School-Age Children (7-12 years)
Moderate risk; school transmission
Previously uncovered
New protection
Adolescents (13-17 years)
Second peak incidence; social mixing
Previously uncovered
Critical gap addressed
Competitive Landscape Analysis
Competitor
Product
Status in China
Age Range
Key Limitations
CanSino Biologics
Menhycia (MCV4)
Approved + expanding
3m-6y → 3m-17y
Market leader; first-mover advantage
Pfizer
Nimenrix (MCV4)
Not approved
Global: 6w+
No China market access
GSK
Menveo (MCV4)
Not approved
Global: 2y+
No China market access
Domestic Manufacturers
Polysaccharide vaccines
Available
Limited age ranges
Inferior immunogenicity vs. conjugate
Commercial Opportunity Assessment
Addressable Population: Expansion adds ~120 million adolescents (ages 7-17) to existing ~90 million children (ages <7)
Vaccination Rates: Current meningococcal vaccination rates in China estimated at <10% for eligible populations
Premium Pricing: Conjugate vaccines command 3-5x premium over polysaccharide alternatives
Public Procurement: Potential inclusion in expanded national immunization program (NIP) for broader age groups
Revenue Impact: Age expansion could increase annual revenue by ¥800 million-¥1.2 billion ($110-170 million) at 15-20% penetration
Market Leadership: Solidifies CanSino’s position as dominant player in China’s meningococcal vaccine market
Strategic Implications
Pipeline Validation: Demonstrates CanSino’s regulatory expertise in managing complex vaccine approvals and expansions
Manufacturing Scale: Existing production capacity positioned to meet expanded demand without significant capital investment
International Potential: Success in China’s large market strengthens foundation for potential global regulatory submissions
Portfolio Diversification: Reduces reliance on COVID-19 vaccine revenue through established routine immunization product
Forward‑Looking Statements This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial prospects for Menhycia. Actual results may differ due to risks including final NMPA approval decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech
By Fineline Cube